Find a Clinical Trial

Showing 1 - 4 out of 4

Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus

2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of BIIB059 in Participants with Active Subacute
Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus
Erythematosus with or without Systemic Manifestations and Refractory
and/or Intolerant to Antimalarial Therapy (AMETHYST)

Cutaneous disorders

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

A Study of Daratumumab-Based Therapies

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Amyloidosis

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Atopic Dermatitis (Eczema)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Atopic dermatitis

All genders

12-17

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (eczema).

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).